Recce Pharmaceuticals Ltd
ASX:RCE
Intrinsic Value
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. [ Read More ]
The intrinsic value of one
RCE
stock under the Base Case scenario is
0.051
AUD.
Compared to the current market price of 0.665 AUD,
Recce Pharmaceuticals Ltd
is
Overvalued by 92%.
RCE's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
RCE or that its price is influenced by factors unrelated to fundamentals.
Recce Pharmaceuticals Ltd's market capitalization is 135.5m AUD.
RCE stock price is 0.665 AUD.
RCE stock (0.051 AUD) is 92% less than its price (0.665 AUD).
RCE. Open DCF Valuation
RCE stock (0.051 AUD) is 92% less than its price (0.665 AUD). Open Relative Valuation
RCE.
RCE's short-term assets (5m AUD) exceed its short-term liabilties (5m AUD).
RCE's long-term assets (5m AUD) exceed its long-term liabilties (5m AUD).
RCE's Revenue is forecast to fall at a rate of 10% per year over the next 3 years.
RCE's Revenue has grown by an exceptional 116% over the past 12 months.
RCE's ROE (Return on Equity) has significantly decreased in the last 3 years from -94% to -1 278%, and is approaching profitability.
RCE's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -2 311% to -93 666%, and is approaching profitability.
RCE has negative Operating Income for the last twelve months.
RCE has negative Net Income for the last twelve months.
RCE's ROE (Return on Equity) for the past 12 months is negative and is equal to -1 278%.
RCE's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -93 666%.
RCE has positive Free Cash Flow for the last twelve months.
RCE's Revenue has been growing by an exceptional 104% per year for the last 3 years.
RCE's D/E (Debt to Equity) is very low and is equal to 0.14.
RCE has negative three-year average ROE (Return on Equity): -305%. The company is not efficient at transforming stockholders' equity into net income.
RCE has negative three-year average ROIC (Return on Invested Capital): -16 695%. The company is not efficient at using invested capital to generate operating income.
RCE has negative Net Debt. This means that the company has more cash and short-term investments (4m AUD) than debt (77k AUD).
RCE's Altman Z-Score is very low and is equal to -6.77.
RCE doesn't generate enough operating income (-11m AUD) to safely cover interest payments on its debt (3k AUD).
Valuation Backtest
Recce Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
RCE
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Recce Pharmaceuticals Ltd
Balance Sheet Decomposition
Recce Pharmaceuticals Ltd
| Current Assets | 4.8m |
| Cash & Short-Term Investments | 4.1m |
| Receivables | 329.5k |
| Other Current Assets | 459.3k |
| Non-Current Assets | 628.8k |
| PP&E | 628.8k |
| Current Liabilities | 4.6m |
| Accounts Payable | 1.7m |
| Accrued Liabilities | 227.8k |
| Other Current Liabilities | 2.7m |
| Non-Current Liabilities | 291k |
| Long-Term Debt | 76.5k |
| Other Non-Current Liabilities | 214.5k |
Earnings Waterfall
Recce Pharmaceuticals Ltd
|
Revenue
|
6.8m
AUD
|
|
Operating Expenses
|
-17.7m
AUD
|
|
Operating Income
|
-10.9m
AUD
|
|
Other Expenses
|
-451.5k
AUD
|
|
Net Income
|
-11.3m
AUD
|
Free Cash Flow Analysis
Recce Pharmaceuticals Ltd
RCE Profitability Score
Profitability Due Diligence
Recce Pharmaceuticals Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Recce Pharmaceuticals Ltd's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
RCE Solvency Score
Solvency Due Diligence
Recce Pharmaceuticals Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Recce Pharmaceuticals Ltd's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RCE Price Targets Summary
Recce Pharmaceuticals Ltd
Shareholder Return
RCE Price
Recce Pharmaceuticals Ltd
| Average Annual Return | 61.33% |
| Standard Deviation of Annual Returns | 116.17% |
| Max Drawdown | -75% |
| Market Capitalization | 135.5m AUD |
| Shares Outstanding | 203 702 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Recce Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm is engaged in development and commercialization of synthetic anti-Infectives designed to address antibiotic resistant superbugs and emerging viral pathogens. The firm pipeline consist of RECCE 327, RECCE 435, and RECCE 529 for viral infections with action against hyper-mutation on bacteria and viruses. Its patent candidate RECCE 327 is an intravenous therapy, which is developed for treatment of serious and potentially life-threatening infections including sepsis due to Gram-positive and Gram-negative bacteria, including their superbug forms. Its RECCE 435 is a broad-spectrum synthetic polymer antibiotic formulated for oral use. Its RECCE 529 is a synthetic polymer anti-infective, which is focused on viral indications. The Company’s RECCE technologies are targeting synergistic unmet medical needs.
Contact
IPO
Employees
Officers
The intrinsic value of one
RCE
stock under the Base Case scenario is
0.051
AUD.
Compared to the current market price of 0.665 AUD,
Recce Pharmaceuticals Ltd
is
Overvalued by 92%.
You don't have any saved screeners yet
